{"database": "openregs", "table": "federal_register", "rows": [["2017-18386", "Product-Specific Guidance for Digoxin; Draft Revised Guidance for Industry; Availability", "Notice", "The Food and Drug Administration (FDA, the Agency, or we) is announcing the availability of a draft revised guidance for industry on generic digoxin tablets entitled \"Draft Guidance on Digoxin.\" The guidance, once finalized, will provide product-specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs) for digoxin tablets.", "2017-08-30", 2017, 8, "https://www.federalregister.gov/documents/2017/08/30/2017-18386/product-specific-guidance-for-digoxin-draft-revised-guidance-for-industry-availability", "https://www.govinfo.gov/content/pkg/FR-2017-08-30/pdf/2017-18386.pdf", "Health and Human Services Department; Food and Drug Administration", "221,199", "The Food and Drug Administration (FDA, the Agency, or we) is announcing the availability of a draft revised guidance for industry on generic digoxin tablets entitled \"Draft Guidance on Digoxin.\" The guidance, once finalized, will provide...", null]], "columns": ["document_number", "title", "type", "abstract", "publication_date", "pub_year", "pub_month", "html_url", "pdf_url", "agency_names", "agency_ids", "excerpts", "regulation_id_numbers"], "primary_keys": ["document_number"], "primary_key_values": ["2017-18386"], "units": {}, "query_ms": 0.44072489254176617, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}